The Case for Investing in Cardiometabolic Health 

Heart disease is the leading cause of death in the U.S., costing $252.2 billion in healthcare services, medications, and lost productivity.¹ By 2050, annual health care costs are projected to triple for cardiovascular conditions, while productivity losses are projected to increase by 54%.²  The economic burden of chronic kidney disease (CKD) is just as staggering – ranging from an average of $3,060 at early stages to over $50,000 annually for those on dialysis treatment.³ 

As employers and payers alike look for solutions to prevent and better manage costly chronic diseases like heart disease and CKD, understanding and supporting members’ cardiometabolic health is critical. This includes providing effective weight management support and obesity care, as obesity is strongly associated with cardiometabolic disorders. 

Cardiometabolic Health: Why It Matters

According to a 2022 study, fewer than 1 out of 14 American adults have optimal cardiometabolic health – putting the majority of Americans on a dangerous track towards disease.⁴ Excess weight is one of the biggest culprits in driving poor metabolic health, and it increases the chances that obesity and other cardiometabolic risk factors will develop, such as:^5,6

• High blood pressure
• High blood sugar levels
• High levels of triglycerides in the blood
• Low levels of HDL (“good”) cholesterol in the blood
• Poor diet

Not only can poor cardiometabolic health lead to heart disease, but it is also a key driver in the development of other cardiometabolic diseases such as stroke, diabetes, insulin resistance, non-alcoholic fatty liver disease, and chronic kidney disease.^7,8 What’s more? Having one of these conditions greatly increases one’s chance of getting another.⁹ 

With the majority of the U.S. population living with poor cardiometabolic health, the prevalence and cost of heart disease and other related conditions will continue to rise. 

The High Cost of Poor Cardiometabolic Health 

Cardiometabolic diseases are a major cause of death worldwide and are associated with poor productivity, absenteeism, and skyrocketing healthcare costs. Annual direct medical costs associated with cardiovascular diseases alone are projected to rise to more than $818 billion by 2030, while lost productivity costs could exceed $275 billion.¹⁰ 

As a whole, $1.1 trillion in healthcare costs are attributed to chronic conditions – including cardiometabolic diseases – and cost U.S. employers a staggering $36.4 billion a year due to missed work.^11,12 

The numbers are clear – without the right interventions to improve cardiometabolic health, chronic disease and the high costs associated with these conditions will continue to plague organizations and their populations. 

“Cardiometabolic health is the foundation of long-term well-being and cost-effective healthcare. By addressing the interconnected factors driving obesity, diabetes, and heart disease, organizations can prevent costly chronic conditions before they escalate, “ says Robyn Racheotes, Vice President of Payers and Providers at Noom. “Investing in comprehensive cardiometabolic solutions isn’t just about better health outcomes — it’s about ensuring a healthier, more productive workforce while driving sustainable cost savings.”

Take Action with Complete Cardiometabolic Solutions Driven by Behavior Change

While disease management solutions can help people better manage their chronic conditions and control costs, payers and employers must also prioritize prevention to mitigate risk factors, improve outcomes, and drive costs down long term. 

Organizations can focus on prevention by helping their populations develop healthier, sustainable habits and lifestyles. The key to this is empowering long-term behavior change through comprehensive cardiometabolic solutions that support your whole population. 

“Noom’s comprehensive approach to cardiometabolic health ensures users have the tools they need to develop lasting habits that drive lasting health outcomes,” says Dr. Adonis Saremi, MD, Noom’s Chief Medical Officer. “Powered by behavior change, Noom’s cardiometabolic programs are designed to improve health by addressing psychological and biological risk factors, helping prevent the onset of chronic diseases and enhancing overall quality of life.” 

Noom Health: A Single Destination for Cardiometabolic Care

Noom offers support for every stage of cardiometabolic health. From weight management and diabetes prevention to diabetes and obesity care, our tailored programs combine coaching, clinical care, data-driven insights, and psychological tools to empower people to take control of their health and reduce long-term risks associated with cardiometabolic disease. We use strategies grounded in cognitive behavioral therapy (CBT) to help members understand the psychological drivers behind their habits. By addressing root causes, our programs provide tools to shift mindsets, break patterns, and build lasting healthy behaviors. 

Here’s how each of the programs can support your population’s cardiometabolic health: 

Noom Weight drives sustainable weight loss and cost savings. 

Our flagship offering has been trusted by millions around the world to achieve lasting weight loss through our unique, psychology-driven approach. Noom Weight helps reduce cardiometabolic risk factors such as excess body fat, obesity, and poor diet through an evidence-based, mind-first approach to help members develop a deeper understanding of the psychological drivers behind their behaviors for lasting change. In fact, 64% of members who lost at least 10% of their weight maintained at least  5% weight loss 2 years after Noom, driving $1,219 in healthcare cost savings over 2 years.^13,14

An extensive and growing body of research proves that mental health is associated with risk factors for cardiovascular disease.¹⁵ Noom enhances holistic health and further drives disease prevention by integrating mental well-being resources into all of our cardiometabolic programs.

Noom Med delivers evidence-based obesity care and compelling ROI. 

Obesity is a key risk factor in the development of cardiometabolic disease and a growing epidemic. Noom Med delivers high-quality, sustainable outcomes through evidence-based obesity care, combining intensive lifestyle intervention and psychology with medication-assisted weight loss, as needed, to maximize ROI. 

Noom Med helps optimize the efficacy of GLP-1s to drive sustainable weight loss for members with obesity, reducing their risk of developing cardiometabolic disease. Users who added Noom to an early GLP-1 reported losing over 39% more weight on average compared to GLP-1 only users.¹⁶ 

Noom Med leverages a step therapy approach to help rightsize GLP-1 use to prevent uncontrolled healthcare spending while boosting employee health outcomes, resulting in cost savings beyond medication alone. This all leads to a projected 4.1X ROI over a three-year period for employers and payers looking to manage healthcare costs while improving health outcomes.¹⁷ 

Noom Diabetes Prevention Program lowers diabetes risk and improves overall health.

As one of very few digital programs to earn CDC Full Plus recognition, Noom’s Diabetes Prevention Program is uniquely positioned to help organizations prevent the onset of type 2 diabetes by reducing risk factors associated with poor cardiometabolic health, such as being overweight –  even modest weight loss can lower diabetes risk by 58%.¹⁸ 

We carefully monitor each member’s routine and teach the fundamentals of healthy nutrition, exercise, stress management, and sleep hygiene. This deepens their awareness of the areas to focus on, and helps them implement changes and ultimately sustain a healthy routine. Over half of users (64%) prevented or delayed the onset of type 2 diabetes, while 66% of engaged members lost at least 5% of their body weight.^19,20 Those who completed the one-year program saw a 0.28% reduction in HbA1c.²¹

Noom Diabetes Management lowers A1C levels and reduces costs. 

Available in late 2025, Noom’s Diabetes Management solution offers a comprehensive, psychology-driven approach to help members with type 2 diabetes control their A1C. In fact,  55% users achieve clinically significant A1C reduction in 3 months.²² Noom makes diabetes management simple — combining lifestyle change and medication support, all in one platform. Through comprehensive support powered by behavior change, Noom Diabetes Management drives sustainable change to improve outcomes and prevent the onset of additional cardiometabolic diseases. 

Ready to put your population on the path to better cardiometabolic health? See which of Noom Health’s proven cardiometabolic programs is right for your organization. 

References

¹https://www.cdc.gov/heart-disease/data-research/facts-stats/.

²https://www.ahajournals.org/doi/10.1161/CIR.0000000000001258.

³https://pubmed.ncbi.nlm.nih.gov/37493856/.

⁴https://peakheart.com/only-68-of-americans-are-in-optimal-cardiometabolic-health/. 

⁵https://www.health.harvard.edu/blog/how-good-is-your-cardiometabolic-health-and-what-is-that-anyway-202208182803.

⁶https://southdenver.com/what-is-cardiometabolic-disease/.

⁷https://medicine-vet-medicine.ed.ac.uk/our-research/research-themes/cardiometabolic-diseases.

⁸ https://www.ahajournals.org/doi/10.1161/cir.0000000000001184.

⁹https://www.labcorp.com/cardiometabolic-diseases/providers.

¹⁰https://www.cdcfoundation.org/pr/2015/heart-disease-and-stroke-cost-america-nearly-1-billion-day-medical-costs-lost-productivity.

¹¹https://business.kaiserpermanente.org/california/care-value/managing-costs/chronic-conditions.

¹²https://www.upmchealthplan.com/employers/blog/wellness/chronic-conditions.

¹³CN May et al. “Weight Loss Maintenance After a Digital Commercial Behavior Change Program (Noom Weight).” https://pmc.ncbi.nlm.nih.gov/articles/PMC10551118/. 

¹⁴The Impact of a Digital Weight Loss Intervention on Health Care Resource Utilization and Costs Compared Between Users and Nonusers With Overweight and Obesity: Retrospective Analysis Study.

¹⁵https://www.cardiometabolichealth.org/mental-health-month-the-intersection-of-mental-illness-and-cardiometabolic-disease/.

¹⁶Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the Noom program when being prescribed an early stage GLP-1.

¹⁷This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled.

¹⁸CDC. “Prediabetes – Your Chance to Prevent Type 2 Diabetes.” https://www.cdc.gov/diabetes/prevention-type-2/prediabetes-prevent-type-2.html. 

¹⁹ Noom internal retrospective analysis of data from 2021-2022.

²⁰Usefulness of a novel mobile Diabetes Prevention Program delivery platform with human coaching. May 2018. An engaged user is defined as a participant who completed the 24-week intervention and took any in-app action during the maintenance phase (weeks 24-65).

²¹Mobile delivery of the Diabetes Prevention Program in people with prediabetes:a randomized controlled trial. July 2020. A program completer is defined as any participant who finished the 12-month intervention.

²² Based on a 3-month study integrating Noom Diabetes Support with a smart glucose monitor.